Get the Stockscreener App
59.56
0.03%
-0.06
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.56, with a volume of 3.28M.
It is down -0.03% in the last 24 hours and down -0.58% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$59.62
Open:
$59.75
24h Volume:
3.28M
Relative Volume:
0.32
Market Cap:
$120.52B
Revenue:
$48.30B
Net Income/Loss:
$-8.95B
P/E Ratio:
-13.48
EPS:
-4.42
Net Cash Flow:
$13.94B
1W Performance:
+2.97%
1M Performance:
-0.58%
6M Performance:
+17.97%
1Y Performance:
+17.12%
1-Day Range:
$59.01
$59.75
1-Week Range:
$56.96
$59.94
52-Week Range:
$39.35
$61.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.57 | 120.52B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
932.11 | 876.70B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.25 | 398.98B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
211.99 | 372.17B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
166.43 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.52 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Los Angeles Capital Management LLC - MarketBeat
Union Bancaire Privee UBP SA Buys Shares of 5,908 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Investors Purchase High Volume of Call Options on Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Atrial Fibrillation Market Detailed In New Research Report 2025 | Bristol-Myers Squibb Company, Johnson & Johnson - openPR
Bristol Myers Squibb Co. to Host Earnings Call - ACCESS Newswire
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report - TradingView
Bristol-Myers Squibb (BMY) Announces Executive Vice President's Retirement - GuruFocus.com
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Oppenheimer & Co. Inc. - MarketBeat
Mn Services Vermogensbeheer B.V. Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Howard Capital Management Inc. Purchases 6,416 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
William Blair Has Bearish Forecast for BMY FY2027 Earnings - MarketBeat
Immuno-oncology Drugs Market Is Booming Across the Globe | Coloplast Corp, Bristol Myers Squibb Company - openPR
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by First Horizon Advisors Inc. - MarketBeat
Bristol-Myers Squibb Company (BMY): Top Stock to Buy from Dividend Stock Portfolio For Income - Insider Monkey
Bristol-Myers Squibb's SWOT analysis: stock faces growth challenges amid pipeline promise - Investing.com
Bristol Myers Squibb Caps 2024 with Strong Q4 Growth, Bolstered by Key Products and Pipeline Advances - BSA bureau
Bristol-Myers Squibb, Adnexus in oncology tie-up - Reuters
Why Bristol-Myers Squibb Co (BMY) Went Up On Monday? - Yahoo Finance UK
NICE recommends Bristol Myers Squibb’s lymphoma treatment - Pf Media
How to Access Bristol Myers Squibb Management's Latest Strategic Insights This March - StockTitan
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Starbucks, Bristol Myers Squibb, Home Depot - TradingView
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review - Benzinga
Bristol Myers Squibb (BMY) Gains FDA Acceptance for Opdivo-Yervoy Combo in MSI-H/dMMR Colorectal Cancer - HPBL
Bristol Myers rises after FDA accepts application for combo drug for colorectal cancer - TradingView
Bristol Myers: file accepted in colorectal cancer -February 24, 2025 at 07:36 am EST - Marketscreener.com
FDA reviews Bristol Myers Squibb's dual therapy for colorectal cancer - Investing.com
Q1 EPS Estimate for Bristol-Myers Squibb Lowered by Analyst - MarketBeat
Insider Buying: Christopher Boerner Acquires Shares of Bristol-M - GuruFocus.com
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week - MSN
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week (BMY:NYSE) - Seeking Alpha
Bristol Myers Squibb CEO Christopher Boerner buys $110,096 in stock - Investing.com
Bristol Myers Squibb CEO Christopher Boerner buys $110,096 in stock By Investing.com - Investing.com UK
Bristol Myers Squibb CEO Acquires 2,000 Shares - TradingView
GC Sandra Leung Leaving Bristol-Myers After 33 Years - Law360
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success - Seeking Alpha
BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com
Cell Therapy Market Is Booming So Rapidly with Forecast by 2032 | Bristol Myers Squibb Company, Amgen, Johnson - EIN News
Paradigm Asset Management Co. LLC Has $2.23 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Clinical Trial Manager Job – at Bristol Myers Squibb, Apply Now! - BioTecNika
Braun Stacey Associates Inc. Makes New $19.71 Million Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
High Potency Drug Market Top PlayersNovartis AG, Bristol-Myers Squibb Co, Sanofi, Takeda Pharmaceutical Co Ltd. - openPR
Truist Financial Corp Purchases 60,365 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb veteran general counsel to retire - | Governance Intelligence
GAM Holding AG Sells 39,363 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Names New GC as Legal Chief Retires - Bloomberg Law
FTC clears BioArctic’s deal with BMS - The Pharma Letter
Compugen Updates Filing Structure with Bristol Myers Squibb - MSN
BioArctic-Bristol Myers Squibb Alzheimer's Deal Clears US Regulatory Hurdle -February 20, 2025 at 01:43 am EST - Marketscreener.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.12%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):